Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 7/20 | 0.55 |
| ▸ | ESR2 | Q92731 | 4/20 | 0.55 |
| ▸ | PGR | P06401 | 2/20 | 0.55 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.54 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | CA3 | P07451 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | TYR | P14679 | 1/20 | 0.52 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.52 |
| ▸ | CA4 | P22748 | 1/20 | 0.52 |
| ▸ | CA6 | P23280 | 1/20 | 0.52 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | CA5A | P35218 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3617904 | 1.00 | ESR1 (0.55) | ESR1ESR2PGRHSD17B3HPGD | |
| SCHEMBL5694679 | 0.86 | ESR1 (0.62) | ESR1ESR2PGRSMN1; SMN2L3MBTL1 | |
| SCHEMBL5694682 | 0.86 | ESR1 (0.62) | ESR1ESR2PGRSMN1; SMN2L3MBTL1 | |
| Butane SCHEMBL67951 | 0.82 | ESR1 (0.58) | ESR1ESR2PGRHPGDSMN1; SMN2 | |
| SCHEMBL5694693 | 0.81 | CA12 (0.65) | ESR1HSD17B3HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL5694694 | 0.81 | CA12 (0.65) | ESR1HSD17B3HPGDSMN1; SMN2L3MBTL1 | |
| SCHEMBL3614748 | 0.81 | KDM4E (0.55) | ESR1ESR2PGRHPGDSMN1; SMN2 | |
| SCHEMBL3614745 | 0.81 | KDM4E (0.55) | ESR1ESR2PGRHPGDSMN1; SMN2 | |
| SCHEMBL8576829 | 0.80 | HSD17B3 (0.64) | HSD17B3HPGDSMN1; SMN2L3MBTL1KDM4E | |
| SCHEMBL9337930 | 0.79 | HSD17B3 (0.55) | ESR1ESR2HSD17B3HPGDSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2014-11-13 | — | — | US | disclosed |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2010-06-03 | — | — | US | disclosed |
| EP-1928848-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | Apogee Biothechnology Corporation (US) | 2008-06-11 | — | — | EP | disclosed |
| WO-2007019251-A9 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORP (US) | 2007-04-19 | — | — | WO | disclosed |
| WO-2007019251-A2 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-15 | — | — | WO | disclosed |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | APOGEE BIOTECHNOLOGY CORPORATION (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1094055-B1 | NOVEL VINYLBENZENE DERIVATIVES | SANTEN PHARMACEUTICAL CO LTD (JP) | 2006-04-26 | — | — | EP | disclosed |
| US-6329547-B1 | USEFUL AS THERAPEUTIC AGENTS FOR GLAUCOMA | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-12-11 | — | — | US | disclosed |
| EP-1094055-A1 | NOVEL VINYLBENZENE DERIVATIVES | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2001-04-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140335050-A1 | METHODS, COMPOSITIONS, AND KITS FOR THE TREATMENT OF CANCER | IL2RA, CD74, IL2 | ESR1 2104/4885ESR2 975/4885PGR 1158/4885 |
| US-20070032531-A1 | SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE | SPHK1, SPHK2, S1PR2 | ESR1 4551/4885ESR2 3368/4885PGR 3824/4885 |
| US-20100137315-A1 | Sphingosine Kinase Inhibitors and Methods of Their Use | SPHK1, SPHK2, S1PR2 | ESR1 4555/4885ESR2 3454/4885PGR 3876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.